1354690-24-6

Basic information

• Product Name: 1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one
• Synonyms: 1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one
• CAS NO: 1354690-24-6
• Molecular Weight: 450.464
• Mol File: 1354690-24-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one(1354690-24-6)
• EPA Substance Registry System: 1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one(1354690-24-6)

Safety Data

• Hazardous Substances Data: 1354690-24-6(Hazardous Substances Data)

Usage

General Description

1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one is a complex chemical compound with a long and specific name. It belongs to the class of pyrrolidine compounds and contains a pyrimidine ring as well as a pyridine ring. It also has a methoxy group and a trifluoromethyl group attached to the pyridine ring. 1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one may have pharmacological properties, potentially acting as a receptor agonist or antagonist. Due to its structure and composition, it likely has a specific mode of action within biological systems, potentially influencing various physiological processes. The compound's precise function and potential applications would need to be determined through further research and experimentation.

Upstream product

• 1354691-73-8 (S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 79-03-8 propionyl chloride 
• 147081-44-5 (3S)-3-amino-1-(tert-butoxycarbonyl)-pyrrolidine 
• 1214377-42-0 5-bromo-2-methoxy-3-(trifluoromethyl)pyridine 
• 1354691-72-7 (S)-3-(5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1354691-71-6 (S)-3-(6-benzyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 914612-23-0 6-benzyl-4-chloro-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine 
• 121643-44-5 2-methoxy-3-(trifluoromethyl)pyridine 
• 1354692-00-4 [6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-(S)-pyrrolidin-3-yl-amine 
• 65753-47-1 2-chloro-3-trifluoromethyl-pyridine 

Downstream Products

• 1354691-99-8 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one hippurate 

Relevant articles and documents

Design of A Metabolically Stable Tritium-Tracer of the PI3Kδ-Inhibitor CDZ173 (Leniolisib) as a Tool to Study Liver Metabolites

In this disclosure, we summarize the preliminary metabolic profiling of the PI3Kδ inhibitor CDZ173 (leniolisib, 1a) obtained from incubations of the unlabeled compound and the synthesis of its metabolically stable tritium isotopologue 1b used for metaboli

Use of Inhibitors of the Activity or Function of PI3K

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES

The invention relates to crystalline anhydrous forms, crystalline solvate forms and/or salt forms including crystalline salt forms of {(S)-3-[6-(6-methoxy-5-methyl-pyridin-3-yl)-5,6,7,8- tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone or salt forms including crystalline salt forms of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl- pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-on; pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.